<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587015</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-8015-1003</org_study_id>
    <nct_id>NCT00587015</nct_id>
  </id_info>
  <brief_title>A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be&#xD;
      safely administered to a patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To estimate the maximum tolerated dose (MTD), defined as the highest dose that can be safely&#xD;
      administered to a patient, and to establish a safe dose, based on MTD, for subsequent&#xD;
      clinical testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to a lack of IP supply and then terminated because they were combined into one new study&#xD;
    with the new IP formulation.&#xD;
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety, estimate MTD, characterize toxicity profile, study pharmacology and observe anti-tumor activity at the MTD.</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess immunogenicity of CAT 8015 and potential biomarkers for therapeutic or toxicity responses.</measure>
    <time_frame>Day 0-7; 0-14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAT-8015</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-8015</intervention_name>
    <description>The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to be eligible to participate in the&#xD;
        study:&#xD;
&#xD;
          -  Confirmed diagnosis of B-cell non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Evidence of CD22-positive malignancy by the following criteria, &gt; 30% of malignant&#xD;
             cells from a disease site CD22+ by FACS analysis or, &gt; 15% of malignant cells from a&#xD;
             disease site must react with anti-CD22 by immunohistochemistry&#xD;
&#xD;
          -  Disease characteristics: Patients with indolent subtypes of CD22+ B-cell non-&#xD;
             Hodgkin's lymphoma, including, but not limited to mantle cell lymphoma, follicular&#xD;
             lymphoma and Waldenström's macroglobulinemia, are eligible if stage III-IV. if stage&#xD;
             III-IV. Patients must have failed at least two or more courses of prior standard&#xD;
             chemotherapy and/or biologic therapy (e.g. Rituxan). Patients with progressive mantle&#xD;
             cell lymphoma may be eligible if they have failed one prior standard therapeutic&#xD;
             regimen.&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Patients with other cancers who meet eligibility criteria and have less than 5 years&#xD;
             of disease free survival will be considered on a case-by-case basis&#xD;
&#xD;
          -  Life expectancy of less than 6 months, as assessed by the principal investigator&#xD;
&#xD;
          -  Must be able to understand and sign informed consent&#xD;
&#xD;
          -  Must be at least 18 years old&#xD;
&#xD;
          -  Female and male patients must agree to use an approved method of contraception during&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria are not eligible for participation in the&#xD;
        study:&#xD;
&#xD;
          -  History of allogeneic bone marrow transplant&#xD;
&#xD;
          -  Documented and ongoing central nervous system involvement with their malignant disease&#xD;
             (history of CNS involvement is not an exclusion criterion)&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  HIV positive serology (due to increased risk of severe infection and unknown&#xD;
             interaction of CAT-8015 with antiretroviral drugs)&#xD;
&#xD;
          -  Hepatitis B surface antigen positive&#xD;
&#xD;
          -  Uncontrolled, symptomatic, intercurrent illness including but not limited to:&#xD;
             infections requiring systemic antibiotics, congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Patients whose plasma contains either a significant level of antibody to CAT-8015 as&#xD;
             measured by ELISA, or antibody that neutralizes the binding of CAT-8015 to CD22 as&#xD;
             measured by a competition ELISA.&#xD;
&#xD;
        Hepatic function Serum transaminases (either ALT or AST) or bilirubin:&#xD;
&#xD;
          -  ≥ Grade 2, unless bilirubin is due to Gilbert's disease&#xD;
&#xD;
        Renal function:&#xD;
&#xD;
          -  serum creatinine clearance ≤ 60mL/min as estimated by Cockroft-Gault formula&#xD;
&#xD;
        Hematologic function:&#xD;
&#xD;
          -  The ANC &lt; 1000/cmm, or platelet count &lt;50,000/cmm, if these cytopenias are not judged&#xD;
             by the investigator to be due to underlying disease (i.e. potentially reversible with&#xD;
             anti-neoplastic therapy).&#xD;
&#xD;
          -  A patient will not be excluded because of pancytopenia ≥ Grade 3, or erythropoietin&#xD;
             dependence, if it is due to disease, based on the results of bone marrow studies&#xD;
&#xD;
          -  Baseline coagulopathy greater than or equal to Grade 3 unless due to anticoagulant&#xD;
             therapy.&#xD;
&#xD;
        Pulmonary function:&#xD;
&#xD;
          -  Patients with &lt; 50% of predicted forced expiratory volume (FEV1) or &lt;50% of predicted&#xD;
             diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin concentration&#xD;
             and alveolar volume. Note: Patients with no prior history of pulmonary illness are not&#xD;
             required to have PFTs. FEV1 will be assessed after bronchodilator therapy.&#xD;
&#xD;
        Recent prior therapy:&#xD;
&#xD;
          -  Cytotoxic chemotherapy, corticosteroids (except stable doses of prednisone), whole&#xD;
             body electron beam radiation therapy, hormonal, biologic or other standard or any&#xD;
             investigational therapy of the malignancy for 3 weeks prior to entry into the trial&#xD;
&#xD;
          -  Less than or equal to 1 month prior monoclonal antibody therapy (i.e. rituximab)&#xD;
&#xD;
          -  Patients who are receiving or have received radiation therapy less than 3 weeks prior&#xD;
             to study entry will be not be excluded providing the volume of bone marrow treated is&#xD;
             less than 10% and also the patient has measurable disease outside the radiation port&#xD;
&#xD;
          -  Any history of prior pseudomonas-exotoxin immunotoxin (PE) administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Leechleider, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Hematology Oncology Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211-1850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI, National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalinika Hemotologii Uniwersytetu Medycznego</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunotoxin HA22</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

